Tag Archives: research and development

9th Annual Patients as Partners® Europe Event to Focus on Advancing Patient Involvement in Clinical Research

NEW YORK, NY, United States, 11-Feb-2025 — /EuropaWire/ — The Conference Forum has announced the 9th annual Patients as Partners® Europe event, set for May 20-21, 2025, at the Royal National Hotel in London. This event provides a unique platform for pharma R&D professionals and patient advocates to discuss how patient involvement can reduce risks and inefficiencies in clinical research while advancing the development of new treatments.

Alfred Samuels, a patient advocate and co-chair for 2025, emphasized the importance of recognizing patients as experts in their conditions, which leads to more successful trials and better healthcare outcomes.

Keynote speakers include:

  • Harry Verbunt, who will share his post-cancer clinical trial experience and suggestions for improving trial access.
  • Peter DiBiaso, discussing the importance of placing patients at the center of research.
  • Dr. Temi Olonisakin, offering patient perspectives on support in clinical research.
  • Lea-Isabelle Proulx, PhD (Roche), on reducing patient burden through improved protocols.
  • Beyza Klein (Johnson & Johnson), on embedding a patient engagement strategy.
  • Dr. Catherine Coulouvrat (Sanofi), discussing how patient experience data informs product tolerability.
  • Marisa Minetti (Chiesi Farmaceutici), on leveraging patient archetypes in protocol development.
  • Gisela Linthorst (Azafaros), on involving the patient community in early clinical trials.

Pharma companies such as AstraZeneca, Boehringer-Ingelheim, GSK, and others will also present case studies on advancing patient partnerships.

The event will explore critical topics including patient-informed research, decentralized trials, increasing trial representation, and reducing patient burden through technology.

Patients as Partners® Europe is co-produced with patients, R&D, academia, and non-profit organizations to advance patient involvement and access. For more details, visit PatientsAsPartnersEU.com.

About the Conference Forum: The Conference Forum is a life science industry leader in organizing conferences, webinars, and digital content, driving efficient medicine development and patient access. Learn more at theconferenceforum.org.

SOURCE: EuropaWire

Dr. Christina Marrongelli chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference in Paris

Dr. Christina Marrongelli chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference in Paris

Marrongelli selected for her expertise in Botanical Drug Development

LONDON, Jun-16-2018 — /EPR Healthcare News/ — As a leading expert in her field, Dr. Christina Marrongelli, PharmD has been chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to moderate their 2018 conference: Exploring New Trends & Innovations in Pharmacology and Natural Compounds. The conference is being held in Paris, France on June 18, 2018.

Dr. Marrongelli, who is an adjunct professor at the Medical University of South Carolina in the department of drug discovery and biomedical sciences will also present “Developing and Marketing Botanical Drugs in the United States”.

The United States, which has the largest pharmaceutical market in the world, demonstrates a strong demand for the use of botanicals as medicine. However, to date only two prescription botanical drugs are currently approved for use in the USA: Veregen® (sinecatechins) and Mytesi™Â (crofelemer).

Marrongelli attributes this disconnect between supply and demand to hidden barriers. She notes that with the worldwide herbal drug market is expected to reach nearly $86.74 billion by 2022, businesses must identify and address these barriers so that heterogeneous botanical drug products can obtain the approvals necessary to meet the consumers growing expectations and demands for botanical medicines.

To further explain the barriers to regulation of botanicals, Marrongelli points to the Botanical Drug Development Guidance for Industry from the U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER) that was last updated in 2016. According to publication, regulation of botanicals in the U.S. is different from regulation in the rest of world. The U.S. does not have a separate regulatory category for traditional or herbal medicines: A botanical product may be classified as a food (including a dietary supplement), drug (including a biological drug), medical device, or cosmetic under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Whether an article is a food, drug, medical device, or cosmetic depends in large part on its intended use.

To learn more about the issues and barriers to the development of botanical drugs, please contact Dr. Marrongelli at Marronge@musc.edu or DrM@pharmD.expert.

SOURCE: EuropaWire